MPXV-56 was generated from peripheral blood mononuclear cells obtained from donors who had either recovered from naturally-occurring MPXV infection or been immunized against vaccinia5.
≥ 5.0 mg/ml
< 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Standard Overnight on Blue Ice.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Anti-MPXV A35R (clone name: MPXV-56) is reactive against the EV membrane protein encoded by ORF A35R of monkeypox virus (Homologous to Vaccinia virus A33R).
Complementary screening approaches were used to identify orthopoxvirus-specific mAbs to MPXV, cowpox virus (CPXV), variola virus (VARV), and vaccinia virus (VACV). MPXV-56 is reactive against VACV antigen and lysate, CPXV lysate, MPXV lysate, and VARV antigen and lysate. MPXV-56 binds to VACV and VARV purified antigen and weakly binds virus-infected cell lysates of VACV, CPXV, and MPXV. MPXV-56 neutralizes VACV EV plus complement (+C’) but not MV, MV+C’, or EV.
MPXV-56 also neutralizes CPXV EV+C’ but not EV and weakly neutralizes MPXV EV+C’ but not MV, MV+C’, or EV.
A33 is a surface antigen on the enveloped virion.
Monkeypox virus (MPXV) is a zoonotic member of the Orthopoxvirus genus in the Poxviridae family1. It is the next most pathogenic poxvirus after smallpox. Two genetic clades, West African and Central African (Congo Basin), have been characterized; the latter is capable of human-to-human transmission1,2. Monkeypox has gained clinical relevance due to the eradication of smallpox, which has created opportunities for increased prevalence and viral mutations that may affect virulence1, 2. Rodents are thought to be the natural reservoir, with transmission through contact with bodily fluids and feces. Case fatality rates are <1% and up to 11% for the West African and Central Basin clades, respectively1,2. An infection with one orthopoxvirus of any one species, or vaccinia virus vaccination, protects against infection by other orthopoxviruses3,4,5.
MPXV is an enveloped virus with a linear, double-stranded DNA genome2 and a large, complex proteome of over 200 proteins6. During infection, the virus exists in two antigenically distinct forms: mature virions (MV) or enveloped virions (EV)6.
References & Citations
1. Sklenovská N, Van Ranst M. Front Public Health. 6:241. 2018.
2. Moore M, Zahra F. 2021 Oct 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.
3. McConnell S, Herman YF, Mattson DE, et al. Am J Vet Res. 25:192-195. 1964.
4. Hammarlund E, Lewis MW, Carter SV, et al. Nat Med. 11(9):1005-1011. 2005.
5. Gilchuk I, Gilchuk P, Sapparapu G, et al. Cell. 167(3):684-694.e9. 2016.
6. Moss B. Immunol Rev.239:8–26. 2011.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.